2015
DOI: 10.1016/j.drugpo.2015.04.015
|View full text |Cite
|
Sign up to set email alerts
|

An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential

Abstract: People who inject drugs (PWID) are central to the hepatitis C virus (HCV) epidemic. Opioid substitution treatment (OST) of opioid dependence has the potential to play a significant role in the public health response to HCV by serving as an HCV prevention intervention, by treating non-injection opioid dependent people who might otherwise transition to non-sterile drug injection, and by serving as a platform to engage HCV infected PWID in the HCV care continuum and link them to HCV treatment. This paper examines… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
23
1
1

Year Published

2016
2016
2021
2021

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 38 publications
(25 citation statements)
references
References 98 publications
0
23
1
1
Order By: Relevance
“…daily supervised ingestion of methadone), may result in a subpopulation of PWUD who are more ready and amenable to consider engaging in HCV treatment. Indeed, a growing number of studies suggest that opioid agonist treatment programmes may serve as an important platform to engage PWUD with opioid use disorders in the HCV continuum of care [31]. In contrast, we did not find any impact on willingness to use DAAs of other addiction treatment approaches with less evidence base, including psychosocial-only interventions or withdrawal management alone strategies.…”
Section: Discussioncontrasting
confidence: 88%
See 1 more Smart Citation
“…daily supervised ingestion of methadone), may result in a subpopulation of PWUD who are more ready and amenable to consider engaging in HCV treatment. Indeed, a growing number of studies suggest that opioid agonist treatment programmes may serve as an important platform to engage PWUD with opioid use disorders in the HCV continuum of care [31]. In contrast, we did not find any impact on willingness to use DAAs of other addiction treatment approaches with less evidence base, including psychosocial-only interventions or withdrawal management alone strategies.…”
Section: Discussioncontrasting
confidence: 88%
“…Importantly, enrolment in MMT was positively associated with willingness to use newer HCV treatments. This finding, alongside previous successful experiences of integration of HIV, HCV and addiction treatment, suggests that multidisciplinary one-stop-shop models of care for PWUD may play a critical role in increasing access to HCV treatment and improving treatment outcomes among this population [29][30][31]. The role of addiction treatment in HCV treatment and prevention outcomes should therefore be further explored [14].…”
Section: Discussionmentioning
confidence: 85%
“…Public health policy must effectively and systematically address the availability and accessibility of evidence-based treatment of opioid abuse and dependence (e.g., methadone and buprenorphine) to respond to the current opioid epidemic. (Maremmani & Gerra, 2010; Perlman et al, 2015) Programs to prevent fatal overdoses, such as naloxone distribution programs, are critical in addressing preventable drug use-related deaths. (CDC, 2012b) Transition to heroin is an additional and key concern related particularly to misuse of prescription opioids; heroin use has increased in the US by 145% since 2007, and fatal overdoses due to heroin have increased 5-fold during the same time period.…”
Section: 1 Discussionmentioning
confidence: 99%
“…Opioid agonist therapies (OAT), either with methadone or buprenorphine/naloxone, have proved to be effective in reducing illicit opioid use and retaining patients in treatment (Mattick, Breen, Kimber, & Davoli, 2014). OAT has also been shown to reduce illicit drug-related mortality, involvement in criminal activity, as well as to improve HIV and hepatitis C (HCV) prevention and treatment outcomes (Ahamad, et al, 2015; Altice, et al, 2011; Gowing, Farrell, Bornemann, Sullivan, & Ali, 2011; Low, et al, 2016; MacArthur, et al, 2012; Nosyk, et al, 2015; Perlman, et al, 2015). In Canada, methadone maintenance therapy (MMT) has historically been the standard of care of OUD.…”
Section: Introductionmentioning
confidence: 99%